05.20.10
A four-week treatment with the probiotic strain Lactobacillus plantarum 299v (Lp299v) effectively relieves gastrointestinal symptoms, particularly abdominal pain and bloating, in Irritable Bowel Syndrome (IBS) patients fulfilling the Rome III criteria, according to a study presented at Digestive Disease Week (DDW) by Professor Philippe Ducrotté, from Rouen University Hospital, in France.
This randomized, placebo-controlled trial, conducted over a four-week period, involved 214 patients (63 women and 151 men), who fulfilled the Rome III criteria for IBS. The treatment consisted of a daily capsule of placebo or Lp299v (from Institut Rosell-Lallemand), equivalent to 1010 CFU/day. IBS symptoms were monitored (frequency and intensity of abdominal pain, bloating, number of stools, feeling of incomplete rectal evacuation).
After four weeks, Lp299v significantly improved the symptoms, in particular abdominal pain and bloating, as compared to both baseline and the placebo group. The overall patients’ assessment of the treatment efficacy was significantly better in the Lp299v group compared to the placebo group. For further information: www.institut-rosell-lallemand.com